Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (581-590 of 962) with videos related to

Pageof 97
Sort By:
The Lancet. Diabetes & Endocrinology|April 4, 2022
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trialPetr Ostadal, Philippe Gabriel Steg, Yann Poulouin, et al.
International Journal of Cardiology|December 20, 2018
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trialJeremie Abtan, Gregory Ducrocq, Ph Gabriel Steg, et al.
International Journal of Cardiology|May 17, 2021
Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous interventionDeepak L Bhatt, Juan Carlos Kaski, Sean Delaney, et al.
Heart (British Cardiac Society)|September 28, 2011
Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registryP Gabriel Steg, Samir Alam, Chern-En Chiang, et al.
Journal of the American College of Cardiology|September 30, 2017
Physical Activity and Mortality in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Claes Held, Nermin Hadziosmanovic, et al.
European Journal of Preventive Cardiology|August 7, 2013
Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosisJacob A Udell, Ph Gabriel Steg, Benjamin M Scirica, et al.
Journal of the American College of Cardiology|March 20, 2015
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial InfarctionRobert W Yeh, Dean J Kereiakes, Philippe Gabriel Steg, et al.
European Journal of Preventive Cardiology|August 5, 2024
In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programmeDenis Angoulvant, Solène Granjeon-Noriot, Pierre Amarenco, et al.
Lancet (London, England)|January 19, 2010
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyChristopher P Cannon, Robert A Harrington, Stefan James, et al.
Circulation|October 8, 2008
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular riskJohn W Eikelboom, Graeme J Hankey, Jim Thom, et al.
Pageof 97

Showing results (581-590 of 962) with videos related to

Sort By:
Pageof 97
The Lancet. Diabetes & Endocrinology|April 4, 2022
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trialPetr Ostadal, Philippe Gabriel Steg, Yann Poulouin, et al.
International Journal of Cardiology|December 20, 2018
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trialJeremie Abtan, Gregory Ducrocq, Ph Gabriel Steg, et al.
International Journal of Cardiology|May 17, 2021
Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous interventionDeepak L Bhatt, Juan Carlos Kaski, Sean Delaney, et al.
Heart (British Cardiac Society)|September 28, 2011
Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registryP Gabriel Steg, Samir Alam, Chern-En Chiang, et al.
Journal of the American College of Cardiology|September 30, 2017
Physical Activity and Mortality in Patients With Stable Coronary Heart DiseaseRalph A H Stewart, Claes Held, Nermin Hadziosmanovic, et al.
European Journal of Preventive Cardiology|August 7, 2013
Metabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosisJacob A Udell, Ph Gabriel Steg, Benjamin M Scirica, et al.
Journal of the American College of Cardiology|March 20, 2015
Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial InfarctionRobert W Yeh, Dean J Kereiakes, Philippe Gabriel Steg, et al.
European Journal of Preventive Cardiology|August 5, 2024
In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programmeDenis Angoulvant, Solène Granjeon-Noriot, Pierre Amarenco, et al.
Lancet (London, England)|January 19, 2010
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyChristopher P Cannon, Robert A Harrington, Stefan James, et al.
Circulation|October 8, 2008
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular riskJohn W Eikelboom, Graeme J Hankey, Jim Thom, et al.
Pageof 97